Novartis was yet another company to reveal new data on a psoriasis drug at the European Academy of Dermatology and Venereology (EADV) Congress, lifting the lid on data from a range of multinational, real-world studies which reinforced the efficacy of its interleukin-17A inhibitor Cosentyx (secukinumab) in the treatment of moderate-to-severe psoriasis.
The real-world findings indicated a “pronounced improvement” in quality of life, with 59% of patients experiencing little or no detrimental impact from their condition after 24 weeks of treatment. Additionally, Novartis found that 87% of bio-naïve patients remained on Cosentyx after 12 months of treatment.
In the five-year SCULPTURE study, it was found that Cosentyx was the first and only fully human IL-17A inhibitor to show sustained skin clearance rates at five years at Phase 3, while response rates of 90 and 100 on the Psoriasis Area Severity Index (PASI) were almost entirely maintained throughout the five years.
“For both psoriasis patients and doctors, these data confirm that Cosentyx clinical data profile translates into real-world benefits,” said Dr Richard GB Langley, Professor of Dermatology and Director of Research, at Dalhousie University in Canada. “In the everyday management of psoriasis, this provides added reassurance that with Cosentyx, patients achieve and maintain high levels of skin clearance and improved quality of life.”
Eric Hughes, Global Development Unit Head of Immunology, Hepatology and Dermatology at Novartis, added: “This large programme of real-world evidence adds to the robust body of clinical data supporting the use of Cosentyx for psoriasis. As a leader in immuno-dermatology, we are reimagining the lives of psoriasis patients by providing doctors with the best evidence possible, including in real-world settings.”